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Abstract
Background
HIV-disease progression correlates with immune activation. Here we investigated whether
corticosteroid treatment can attenuate HIV disease progression in antiretroviral-untreated
patients.
Methods
Double-blind, placebo-controlled randomized clinical trial including 326 HIV-patients in a
resource-limited setting in Tanzania (clinicaltrials.gov NCT01299948). Inclusion criteria
were a CD4 count above 300 cells/μl, the absence of AIDS-defining symptoms and an
ART-naïve therapy status. Study participants received 5 mg prednisolone per day or pla-
cebo for 2 years. Primary endpoint was time to progression to an AIDS-defining condition or
to a CD4-count below 200 cells/μl.
Results
No significant change in progression towards the primary endpoint was observed in the
intent-to-treat (ITT) analysis (19 cases with prednisolone versus 28 cases with placebo, p =
0.1407). In a per-protocol (PP)-analysis, 13 versus 24 study participants progressed to the
primary study endpoint (p = 0.0741). Secondary endpoints: Prednisolone-treatment
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decreased immune activation (sCD14, suPAR, CD38/HLA-DR/CD8+) and increased CD4-
counts (+77.42 ± 5.70 cells/μl compared to -37.42 ± 10.77 cells/μl under placebo, p <
0.0001). Treatment with prednisolone was associated with a 3.2-fold increase in HIV viral
load (p < 0.0001). In a post-hoc analysis stratifying for sex, females treated with predniso-
lone progressed significantly slower to the primary study endpoint than females treated with
placebo (ITT-analysis: 11 versus 21 cases, p = 0.0567; PP-analysis: 5 versus 18 cases, p =
0.0051): No changes in disease progression were observed in men.
Conclusions
This study could not detect any significant effects of prednisolone on disease progression in
antiretroviral-untreated HIV infection within the intent-to-treat population. However, signifi-
cant effects were observed on CD4 counts, immune activation and HIV viral load. This
study contributes to a better understanding of the role of immune activation in the pathogen-
esis of HIV infection.
Trial Registration
ClinicalTrials.gov NCT01299948
Introduction
Untreated HIV infection causes a progressive loss of helper T-cells that results, after an average
period of about ten years of ongoing virus replication, in immunodeficiency and ultimately
AIDS. HIV infection is also characterized by a general, chronic immune activation that persists
throughout the entire course of infection and that is tightly linked to disease progression.
Patients with higher levels of general immune activation progress more rapidly to T-cell loss
and AIDS than individuals with lower levels [1–5]. For example, long-term non-progressors,
who exhibit reduced levels of immune activation, do not progress to AIDS for a long time,
despite ongoing virus replication [6]. In contrast, elite controllers, who are able to control virus
replication below detection limits, may still progress to AIDS if they have elevated levels of T-
cell activation [7]. Even in the presence of highly-active antiretroviral therapy (HAART),
increased immune activation correlates with higher morbidity and mortality [5, 8–10], a phe-
nomenon that peaks in a special group of patients, the “immunological nonresponders”, who
fail to regain normal T-cell counts despite complete suppression of virus replication under
HAART [11]. The same correlation has been observed in SIV-infected monkeys: The natural
hosts of SIV, African monkeys, remain relatively unaffected by SIV infection and exhibit nei-
ther chronic immune activation nor progression to AIDS despite high-level virus replication,
whereas Asian monkeys develop chronic immune activation and AIDS (reviewed in [12]).
A number of clinical studies describe the importance and predictive value of immune acti-
vation for mortality and non-AIDS comorbidities in HIV infection, including, but not
restricted to, the SMART (acronym for “strategies for management of antiretroviral therapy”),
SCOPE (acronym for “observational study of the consequences of the protease inhibitor era”)
and LSOCA (acronym for “longitudinal study of ocular complications of AIDS”) cohort studies
[5, 13–15]. Consequently, there is a profound interest in immunomodulatory adjunct therapies
that target this immune activation. Different therapeutic strategies have been tested, including
probiotics [16], COX-2 inhibitors [17, 18] and statins [19, 20] (a more extensive review on this
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subject is presented in [21]), and all have shown efficacy in terms of reducing HIV-immune
activation. Corticosteroids belong to another promising substance class to reduce HIV immune
activation. In a prospective but uncontrolled clinical trial, treatment with prednisolone (0.3–
0.5 mg/kg body weight) increased CD4 counts by 119 cells/μl within one year without concom-
itant changes in HIV viral load [22, 23].
To answer the question whether the reduction of immune activation translates into clinical
benefit we need studies with clinical endpoints. Here we report on an investigator-initiated,
interventional, two-year, randomized, placebo-controlled prospective clinical trial in Tanzania
in which we aimed to reduce HIV immune activation with prednisolone in order to monitor
the effects of this intervention on HIV disease progression. When we started the trial, the local
access to HAART was still very limited, so that the Tanzanian National Treatment Guidelines
recommended that asymptomatic HIV patients remained without antiretroviral treatment
when the CD4 count is above 200, a situation that changed only recently in 2012. This rela-
tively late onset of HAART during the study period not only defined the need for cheap and
readily available treatment alternatives, but also allowed us to reach a clinical endpoint (i.e. the
onset of AIDS-defining opportunistic infections) in order to address the question of whether a
reduction of HIV immune activation translates into clinical benefit.
Materials and Methods
Ethics statement
The study was performed according to the declaration of Helsinki and approved by the ethics
committees of the Tanzanian National Institute for Medical Research (NIMR) and the Catholic
University of Health & Allied Sciences, Mwanza. Patient information was provided in Kisua-
heli and in English. Written informed consent was obtained from all study participants. The
study protocol will be made available as Supporting Information (S1 File). The study was
supervised by a data safety monitoring board (DSMB) whose members gave a written report to
the Tanzanian TFDA (Tanzania Food and Drugs Authority) on an annual basis.
Trial registration
The trial was registered at clinicaltrials.gov (NCT01299948). The trial was registered on Febru-
ary 18th, 2011 i.e. after enrollment has begun (FPFV 06/2007). At the time when the trial was
started, the initiators of this study were unfortunately unaware of the policy of the International
Committee of Medical Journal Editors (ICMJE), which requires prospective registration of all
interventional clinical trials. As soon as we became aware of this policy, we registered the
trial. The authors confirm that all ongoing and related trials for this drug/intervention are
registered.
Trial design
An investigator-initiated, two-year, randomized, double-blind, placebo-controlled, single-cen-
ter trial studying the effects of prednisolone per os in a daily dose of 5 mg on HIV disease pro-
gression during the early phase HIV infection (CDC stage A1, A2, B2, B2). A total of 326
patients were randomized; 163 study participants received placebo and 163 study participants
received prednisolone. Clinical and laboratory evaluations were performed before start of treat-
ment (baseline) and at months 1, 2, 3, 4, 5, 6, 9, 12, 15, 18, 21 and 24. FPFV (first patient first
visit) was in 06/2007, and LPLV (last patient last visit) was in 03/2011. The consort checklist
(S1 Checklist), the study protocol (S1 File) and and the minimal data set (S1 Dataset) are avail-
able as Supporting Information to this publication.
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Participants
Patients eligible for the study fulfilled the following criteria: 18 years of age or older, proven
HIV infection according to WHO guidelines, CD4 counts above 300 cells/μl, negative preg-
nancy test, and a CDC stage of A1, A2, B1 or B2. Patients with prior antiretroviral medication,
active tuberculosis, abnormal laboratory results (glucose level>160 mg/dl, liver enzymes
AST and/or ALT 1,5 x ULN, bilirubin 4 x ULN, alkaline phosphatase 5 x ULN,
creatinine 2 mg/dl) or other serious diseases, including psychiatric disorders, were excluded
from the study. The study was performed at the Bugando Medical Center (BMC) in Mwanza,
Tanzania.
Interventions
Study participants received prednisolone per os in a daily dose of 5 mg or placebo self-adminis-
tered by the study participants at home. At each study visit, study participants received suffi-
cient study drug for the period until the next visit. Study participants were asked to return
unused study drug at the next study visit to assess study drug compliance. The protocol
required a minimum drug adherence of greater than 80%. Patients falling below this minimal
drug adherence were not excluded from the study but received intensified counseling on the
proper dosage of the study drug.
Outcomes
The primary endpoint was time to progression to one of the following events: a) death, b) pro-
gression to CDC stage A3 or B3 (i.e. CD4 T-cell count< 200) or progression to CDC stage C
(AIDS-defining illnesses, including tuberculosis). Following progression, study drug medica-
tion was discontinued and study participants received standard antiretroviral medication. At
the beginning of the study (2007) this endpoint was consistent with the “National Guidelines
for the Clinical Management of HIV/AIDS–Tanzania, 2nd edition 2005” of the National AIDS
Control Programme, which recommended HAART at CD4 counts< 200 or for WHO stage 4
disease. In 2009 the national Tanzanian guidelines were updated (3rd edtion, Feb. 2009) and
initiation of HAART was recommended at a) CD4 counts< 200, or at b) CD4< 350 in combi-
nation with a WHO stage-3 disease, or at c) WHO stage 4, regardless of CD4 count. Due to
limitations in supply of antiretroviral medication this recommendation was implemented at
the study site only since 2011 and the endpoint criteria in the study protocol were therefore left
unchanged. In a total of 4 cases in this study these updated criteria were applied to put study
participants on antiretroviral medication. In 2012 the most recent update was released, which
recommends treatment at WHO stages 3 and 4, regardless of CD4 count, or at a CD4
count< 350. By this time, the study had already been completed (LPLV 03/2011).
Sample size
Sample size was calculated according to published data on the effects of prednisolone on CD4
counts [22–25]. This data indicated that the probability of progression to the primary study
endpoint in a two-years period among controls is 0.791. If the true probability of progression
among cases on treatment is 0.625, we would have needed to study 199 participants in the
prednisolone arm versus 199 participants in the placebo arm (as determined by NQuery 3.0
Test, calculated with PS Power and Sample Size Calculations by William D. Dupont and Wal-
ton D. Plummer) to be able to reject the null hypothesis that the progression rates for cases on
treatment and controls are equal with a probability (power) of 0.8. The type I error probability
associated with this test of this null hypothesis is 0.05. The study was therefore designed to
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recruit 200 versus 200 participants. Towards the end of the 12-months recruitment period it
became clear that this number could not be met. The investigators decided to recalculate the
needed sample size using a less-robust test (an uncorrected chi-squared statistic) to reevaluate
this null hypothesis. Using this test, 117 participants in the placebo arm versus 117 participants
in the prednisolone arm were sufficient to reject the null hypothesis. It was therefore decided to
stop recruitment at the scheduled time point at then 163 versus 163 study participants.
Randomization and blinding
We used a computer-generated randomization sequence with a block size of eight to generate a
list that assigned consecutive patient numbers in a 1:1 ratio to active drug or placebo. The ran-
domization list, which was deposited at one of the members of the independent scientific
board of the study (Prof. H. Klinker, Germany), was not accessible to the investigators; also the
block-size remained unknown to the investigators. The study medication was labeled by the
manufacturing company (details see below) with the study numbers assigned to prednisolone
or placebo. Patients who entered the study were assigned to their respective study numbers
(and respective study treatment) in chronological order. The randomization process was super-
vised by “Deutsches Medikamentenhilfswerk action medeor e.V.”. Treatment was double-
blinded during the whole study period, i.e. neither the treating physicians nor the patients did
know what kind of study medication (placebo or active drug) was being allocated.
Study medication
Study medication was prepared by Regal Pharmaceutical Ltd (Nairobi, Kenya). Each tablet
contained 5 mg prednisolone (active component) or lactose (placebo) with identical shape and
color (white). Regal Pharmaceutical Ltd also labeled the study medication with the respective
study patient numbers from the randomization list according to its content. Production was
supervised by “Deutsches Medikamentenhilfswerk action medeor e.V.”.
Clinical evaluation
Study participants were clinically examined at each study visit for vital signs, HIV staging
according to CDC criteria, and pregnancy (urine test). Tuberculosis was tested by sputum test
every three months and by chest X-ray every six months. Malaria was diagnosed on clinical
grounds and generally confirmed by microscopic analysis of blood films. Study participants
diagnosed with malaria received artemether/lumefantrine and, in severe cases, quinine.
Statistical analysis
Study data were subjected to intention-to-treat (ITT) analysis (163 versus 163 study partici-
pants). Estimated proportions of study participants surviving without progression were calcu-
lated using the Kaplan-Meier method. Differences between two survival curves were tested by
log-rank (Mantel-Cox) tests. ANOVA with repeated measures was used to assess differences
between the two treatment arms with respect to CD4 counts. Average changes in CD4 count
per year were calculated using linear regression of changes in CD4 count relative to baseline in
both treatment groups over the two-year study period. We also performed a per protocol (PP)
analysis, in which we included only study participants who had an average minimum study
drug compliance of greater than 80%, i.e. the average study drug adherence of all pill counts
combined had to be greater than 80%. Pill counts of unused study drugs were performed at
3-months intervals at the study visits. The PP population in this manuscript also includes
the study participants who were lost to follow-up and these subjects were censored in the
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Kaplan-Meier analysis. Technically, the PP analysis performed in this manuscript is therefore a
“modified ITT analysis”, as PP analyses usually exclude the data from participants who missed
one or more study visits. Statistics and Graphics were performed using GraphPad Prism 6.0 for
Mac OSX.
Laboratory analyses
CD4 counts were determined at Bugando Medical Center, Tanzania, using a FACScan or a
FACS Calibur cytometer (Becton & Dickinson) during clinical routine. All other laboratory
analyses were performed after storage (-20°C) and dry ice-cooled shipment of the samples at
the University of Würzburg, Germany. HIV viral load (VL) was determined from plasma for
all study participants who continued study drug medication until month 12 at baseline and at
month 12 using a COBAS1 AmpliPrep Instument (Roche Diagnostics). ELISAs to detect
plasma levels of sCD14 (Diaclone), and suPAR (ViroGates) were performed according to the
manufacturer’s instructions. For flow cytometric analysis of frozen PBMC, cells were stained
with with antibodies directed at CD3 (labeled with FITC) and CD8+ (labeled with PerCP) and
counterstained with anti-CD38-PE and anti-HLA-DR (APC) (all antibodies from were pur-
chased from BD Biosciences, Heidelberg, Germany) according to the “lysis no wash” protocol
(BD Biosciences). Cells were analyzed by flow cytometry using a FACS-Calibur four-colour
flow cytometer (Becton Dickinson). We analyzed all events that fell into the FSC/SSC area in
which living lymphocytes usually reside; we did not use any viability dye to discriminate
between live or dead cells due to the limited number of fluorescence detection channels of the
cytometer. Markers were set according to cells stained with fluorochrome-conjugated isotype
control antibodies (all from BD Biosciences). For this analysis, only a very limited number of
samples were available (22 for placebo and 30 for prednisolone), as many baseline PBMC sam-
ples were lost due to freezing or storage problems.
Results
Baseline characteristics
From 06/2007 to 02/2009, 406 study participants were enrolled at Bugando Medical
Center (CONSORT diagram, Fig 1) in the ProCort1 study (trial register clinicaltrials.gov,
NCT01299948). Eighty study participants were excluded from randomization for either not
fulfilling the inclusion criteria (n = 76), or for not having signed the informed consent (n = 2),
or for loss to follow-up before randomization (n = 2). The remaining 326 study participants
were randomized to receive either 5 mg/day prednisolone per os (n = 163) or placebo
(n = 163). All randomized study participants were not yet eligible for treatment with HAART
according to the local Tanzanian National Treatment Guidelines (2nd edition, 2005). Randomi-
zation resulted in an equal distribution of sex in both study arms (80.4.0% females in the pla-
cebo arm versus 81.0% in the prednisolone arm, p = 0.888) (Table 1). Similar distributions
resulted also for age (35.27 vs. 34.09 years, p = 0.221), body-mass index (23.44 vs. 22.15,
p = 0.119), and baseline HIV viral load (4.35 vs. 4.22 log10 copies/ml, p = 0.599). Study partici-
pants in the placebo arm presented at baseline with a median CD4 cell count of 530 cells/μl
compared to 470 cells/μl in the prednisolone arm (p = 0.058). A total of 57.0% of the study par-
ticipants randomized into the placebo arm presented with CD4 counts above 500 cells/μl com-
pared to 44.8% in the prednisolone arm (p = 0.0351). Female study participants presented
with a significantly higher CD4/CD8-ratio than males (0.41 vs. 0.33, p = 0.0387 in the placebo
arm and 0.37 vs. 0.29, p = 0.0083 in the prednisolone arm), a sex-specific difference in the
immune system that has been published previously [26]. Due to differences in body weight
between females and males the fix dose of 5 mg prednisolone per day resulted in a slightly
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higher dose per kg body weight in females compared to males (87.7 μg/kg vs 80.6 μg/kg,
p = 0.0193).
Compliance and follow-up
Compliance with study regimens was estimated by the amount of unused and returned study
drug. Overall compliance was similar in both groups (data not shown) and no difference in
Fig 1. CONSORT statement 2010 flow diagram. The number of participants enrolled, randomized, allocated to study medication, followed-up and analyzed
is shown. Study participants who progressed to the endpoint of the study (CD4 < 200 or CDC stage-C disease) received HAART. In some cases, study
participants also received HAART when they progressed to CD4 < 350 in combination with WHO stage 3-disease. This was in accordance to the National
Tanzanian treatment recommendations Update in 2008 (1 case in the placebo arm and 3 cases in the prednisolone arm). In addition, one patient in the
placebo arm and 2 study participants in the prednisolone arm received HAART without fulfilling either the study endpoint or the criteria listed in the National
Treatment recommendation update.
doi:10.1371/journal.pone.0146678.g001
Table 1. Patient characteristics.
Placebo n = 163 Prednisolone
n = 163
P value* Placebo vs.
Prednisolone
Female Sex (%) 80.4 81.0 P = 0.888
Age (years as mean with S.D.) 35.27 ± 0.70 34.09 ± 0.66 P = 0.221
Body mass index (median) [IQR 25%-75%] 23.44 [20.44–
26.11]
22.15 [20.55–24.70] P = 0.119
CD4 counts (cells/μl, median) [IQR 25%-75%] 530 [395–659] 470 [397–598] P = 0.058
females 531 [394–699] 484 [398–619.5] P = 0.0883
males 519.5 [410.3–
583.3]
447 [380–530] P = 0.2267
P value females vs males P = 0.2638 P = 0.3436 -
CD4/CD8 ratio (median) [IQR 25%-75%] 0.39 [0.30–0.54] 0.35 [0.26–0.54] P = 0.0632
females 0.41 [0.31–0.57] 0.37 [0.27–0.55] P = 0.1558
males 0.33 [0.26–0.49] 0.29 [0.20–0.71] P = 0.1350
P value females vs males P = 0.0387* P = 0.0083** -
CD4 strata  500 cells/μl (%) 57.1 44.8
CD4 strata < 500 cells/μl (%) 42.9 55.2 P = 0.0351§
 500 females 57.3 46.2
< 500 females 42.7 53.8 P = 0.0844§
 500 males 56.2 38.7
< 500 males 43.8 61.3 P = 0.2101§
P value females vs males P = 1.000 P = 0.5483 -
HIV viral load** LOG10 RNA copies/ml (median) [IQR 25%-75%] 4.35 [3.60–4.81] 4.22 [3.75–4.95] P = 0.599
females 4.33 [3.59–4.75] 4.20 [3.75–4.92] P = 0.5542
males 4.57 [3.68–4.98] 4.38 [4.00–5.07] P = 0.7202
P value females vs males P = 0.3446 P = 0.3895 -
study drug dosage relative to body weight (μg/kg, median) [IQR
25%-75%]
82.0 [71.4–90.9] 84.7 [76.9–94.3] P = 0.0535
females 84.7 [72.5–94.3] 87.7 [77.2–98.0] P = 0.0884
males 78.8 [70.4–87.3] 80.6 [74.6–87.7] P = 0.3753
P value of difference females vs males P = 0.0868 P = 0.0193* -
*) P-values were determined using Mann-Whitney U-test if not indicated otherwise.
**) Baseline HIV viral load data available from 86 (placebo) and 80 (prednisolone) study participants. Data as LOG10 of RNA copies/ml.
§) p-value calculated from chi square test for strata  500 cells/μl (%) vs < 500 cells/μl.
doi:10.1371/journal.pone.0146678.t001
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compliance was observed between female and male study participants (Fig 2A and 2B). Com-
pliance declined over time from a median of 98.03% at month 3 to 71.58% at month 21. Of the
326 study participants who underwent randomization, 36 study participants (22.1%) in the
prednisolone group and 41 study participants (25.1%) in the placebo group were lost to follow-
up during the two-year study period (difference p = 0.3903) (Fig 2C). The majority of them did
not attend anymore the visits of the study despite multiple efforts to remind them by telephone.
Others came from rural areas and moved back to their home villages during the study, which
also resulted in the discontinuation of study participation. As depicted in Fig 3A, study partici-
pants who were later lost to follow-up did not present with lower initial CD4 counts at baseline
than study participants who fulfilled the study. Participants who got lost to follow-up also pre-
sented with significantly higher CD4 counts at their last visit than study participants who were
at their next visit diagnosed with AIDS and who received HAART (Fig 3B, p< 0.0001). We
therefore conclude that loss to follow-up in the study was probably not related to HIV disease
progression.
Effects of prednisolone on clinical disease progression
The primary endpoint of the study was progression to CDC stages A3, B3, C or death. This
endpoint was reached if CD4 counts dropped below 200 cell/μl (CDC stage 3) or if an AIDS-
defining condition occurred (CDC stage C), or if the patient died. Study participants who
reached this combined endpoint received HAART. During the study, no patient died and 19
study participants in the prednisolone arm and 28 study participants in the placebo arm
reached the primary study endpoint (Table 2). These numbers were subjected as intent-to-treat
(ITT) to a Kaplan-Meyer analysis (Fig 4A). The difference was statistically insignificant (log-
rank test p = 0.1407).
The protocol defined that the minimum average adherence to the study drug had to be
greater than 80%. In a per protocol (PP) analysis in which we excluded study participants with
an average study drug adherence less than 80%, 13 (prednisolone) versus 24 (placebo) partici-
pants (from a total of 108 and 118, respectively) progressed to the primary end point (Fig 4B,
log-rank test p = 0.0741). The PP analysis that we performed in this study is technically a
“modified ITT analysis”, as we also included the data from participants who were lost to fol-
low-up in order to compensate for the high drop-out rate in our study. If we perform a strict
PP analysis, in which participants who got lost to follow-up are excluded, the number of ana-
lyzed individuals drops to 82 in the prednisolone arm versus 88 in the placebo arm, and the
log-rank test result increases to p = 0.0917 (graph not shown). A post-hoc analysis for progres-
sion to an AIDS-defining condition resulted in 4 (prednisolone) versus 11 (placebo) cases (Fig
4C, log-rank test p = 0.0575). A post-hoc analysis stratified for female sex resulted in 11 (pred-
nisolone) versus 21 (placebo) cases reaching the primary endpoint in the ITT analysis (log-
rank test p = 0.0567, Fig 4D) and 5 (prednisolone) versus 18 (placebo) cases in the PP analysis
(log-rank test p = 0.0051, Fig 4E. (The PP analysis excluding participants lost to follow-up
results in a p = 0.0078, graph not shown). No differences in disease progression between the
placebo- and prednisolone-arm were observed in men (Fig 4G–4I).
As described above, the PP-population in this study is defined as the population with an
average study drug adherence of more than 80%. If we do an analysis restricted to study partici-
pants who never dropped below the required 80% minimum drug adherence, we get a similar
picture as in the PP analysis: No differences in disease progression in men, but a significant
attenuation of disease progression by prednisolone in women (1 in the prednisolone arm ver-
sus 8 in the placebo arm, from a total of 119 and 121, respectively, log-rank test p = 0.0235,
graph not shown).
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Despite the relatively low number of male study participants (about 30 in each arm), the
observed interaction by sex was statistically significant: In the prednisolone arm, females pro-
gressed significantly slower to the primary end point than males (Fig 5B, log-rank-test
p = 0.0110), whereas no differences in disease progression between females and males were
observed in the placebo arm (Fig 5A, log-rank-test p = 0.4831).
In addition to the 19 (prednisolone) and 28 (placebo) study participants who received
HAART for fulfilling the criteria of the primary study endpoint (CD4< 200 or CDC stage-C-
disease), 7 more study participants (5 in the prednisolone group and 2 in the placebo group)
progressed to HAART (Table 2). Four of them (3 in the prednisolone group and 1 in the pla-
cebo group) presented with CD4<350 in combination with a WHO-stage 3-disease. According
to an update in the Tanzanian National treatment guidelines in 2009 that was released during
the study, this was an indication for start of antiretroviral treatment. The other three (2 in the
prednisolone group and 1 in the placebo group) started HAART by discretion of the treating
physician, but without fulfilling either the study endpoint criteria nor the criteria listed in the
National Treatment Guideline Update from 2009. The total number of participants receiving
HAART in the study was therefore 24 (prednisolone) versus 30 (placebo) (Fig 6A–6C shows
the ITT analysis for all sexes (A), females (B) and males (C); no differences were detected). In a
PP analysis, females treated with prednisolone still progressed significantly slower to HAART
than females receiving placebo (log-rank test p = 0.0495, Fig 6E), whereas no differences were
observed in men (log-rank test p = 0.4059, Fig 6F). Fig 7 shows the number at risk for the ITT
and PP populations of the Kaplan-Meyer analyses depicted in the Figs 4 and 6 for all sexes
(Fig 7A), females (Fig 7B), and males (Fig 7C).
Effects of prednisolone on CD4 counts
Prednisolone treatment had a stabilizing effect on CD4 counts, with an average increase
of +77.42 (± 85.70) cells/μl for prednisolone during the 2-year study period calculated by linear
regression (p< 0.0001) (Fig 8B). In contrast, study participants treated with placebo experi-
enced a significant decline of CD4 counts by -37.49 (± 10.77) cells/μl (p = 0.0005). Differences
in CD4 changes between the two treatment groups were statistically significant (p< 0.0001).
The difference in absolute CD4 counts between the two treatment arms did not reach statistical
significance (p = 0.1938) (Fig 8A). Prednisolone treatment also significantly improved the
CD4/CD8 ratio of the study participants compared to placebo (p< 0.0001) (Fig 8C). These
positive effects of prednisolone on CD4 cell counts and CD4/CD8 ratio were even more pro-
nounced when analyzing female study participants separately. In contrast, no effects were
observed in male study participants (Fig 8D–8F for females and Fig 8G–8I for males).
Effects of prednisolone on immune activation and viral load
Treatment with prednisolone resulted in a moderate but significant reduction of immune acti-
vation (Fig 9). Soluble CD14 (sCD14) as well as soluble urokinase-type plasminogen activator
receptor (suPAR), two plasma markers that have been described to correlate with HIV disease
progression [5, 27], were significantly decreased following prednisolone treatment compared
to placebo (Fig 9A and 9B). Coexpression of CD38 and HLA-DR on CD8-positive T-cells, a set
of markers that have previously been described as a very reliable progression marker for HIV
Fig 2. Study drug adherence and loss to follow-up. A, B: Study drug adherence calculated from pill counts
of returned, unused study medication in female (A) and male (B) study participants. P-values were calculated
by 2way ANOVAC: Loss to follow-up during the two-year study. P value was calculated by log-rank (Mantel-
Cox) analysis.
doi:10.1371/journal.pone.0146678.g002
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disease [2, 3, 7, 8], was also significantly reduced in the prednisolone arm (Fig 9C). The number
of samples that we could use for this analysis was limited due to freezing problems of the
PBMC during storage and shipment (n = 22 for placebo versus n = 30 for prednisolone). We
also determined HIV viral load from 166 available plasma sample pairs from baseline and
month 12. As depicted in Fig 9D, prednisolone treatment caused a statistically significant
Fig 3. CD4 counts of study participants with loss of follow-up. A: Baseline (BL) CD4 counts from study
participants who were later lost to follow up (lost) and who fulfilled (fulfilled) the study. P value was calculated
by Mann-Whitney test.B: CD4 counts prior to loss to follow up (loss) or to progression to the primary endpoint
(HAART). Red bars (placebo) and blue bars (prednisolone) represent medians. P values were calculated by
Kruskal-Wallis test with multiple comparisons.
doi:10.1371/journal.pone.0146678.g003
Table 2. Clinical endpoints and other reasons for initiating HAART.
Reasons for initiating HAART Prednisolone Placebo
Clinical study endpoints
AIDS-deﬁning conditions Overall 4 11
Candidiasis oesophageal 0 1
Cervix carcinoma 0 1
Kaposi sarcoma 0 1
M. tuberculosis disease 3 3
Toxoplasmosis of the brain 0 1
P. jirovecii pneumonia 1 1
Pneumonia recurrent 0 2
Wasting syndrome 0 1
CD4 < 200 15 17*
Death 0 0
total reaching clinical study endpoint 19 28
Non-endpoints§§
CD4 < 350 and WHO stage 3§ Overall 5 2
candidiasis, oropharyngeal 1 0
cough, fever, weight loss 1 0
fever, prolonged 0 1
tonsillitis, pneumonia 1 0
other reasons# candidiasis, oral, CD4 of 380 cells/μl 1 0
asymptomatic, low CD4 count, but above 200 (203 and 201) 1 1
total receiving HAART 24 30
*) one patient receiving placebo developed an AIDS-deﬁning condition with CD4 counts < 200. In this table this patient was only listed under AIDS-
deﬁning conditions, and not also under the CD4 criterion.
§) During the study, the National Treatment guidelines in Tanzania were updated in 2009. Since then, the initiation of HAART was indicated at WHO stage
4, or at CD4 counts < 350 cells/μl if a (non-AIDS-deﬁning) opportunistic infection (WHO stage 3) is present. Due to difﬁculties in drug supply this update
was fully implemented at out study site only since 2011. A total of 4 study participants fulﬁlled this condition and discontinued participation in the study and
received HAART.
#) In one case the decision to initiate HAART was not in accordance with the study protocol or the national guidelines, but was done at the discretion of
the treating clinician. Before initiation of HAART at study month 4, and with a CD4 count of 380 cells/μl and a non-AIDS-deﬁning condition (oral
candidiasis), the patient presented with stable CD4 counts of 723 cells/μl (baseline), 754 cells/μl (month 1), 524 cells/μl (month 2), and 812 cells/μl (at
month 3). CD4 counts continued to be stable immediately after initiation of HAART (486 cells/μl at week 6 and 714 cells/μl at week 10). In two cases,
HAART was initiated in asymptomatic infection at 203 (prednisolone) and 201 (placebo) cells/μl.
§§) These study participants were censored in the Kaplan-Meyer analysis.
doi:10.1371/journal.pone.0146678.t002
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increase in HIV viral load at month 12 compared to baseline by a factor of 3.2 (median 1.65 x
104 copies/ml at baseline compared to median 5.28 x 104 copies/ml at month 12, p< 0.0001,
Wilcoxon matched-pairs signed rank test).
In order to detect any effects related to sex [28], we performed a post-hoc analysis and ana-
lyzed the outcome for female and male study participants separately. A reduction of immune
activation was most pronounced in females (Fig 9E–9G), whereas only little effects were
observed in men (Fig 9I–9K). In contrast to immune activation, the enhancing effects of pred-
nisolone on HIV viral load could be detected both in females and in males (Fig 9H and 9L).
Adverse events
The rate of adverse events, including typical side effects of higher-dose prednisolone, was not
elevated during prednisolone treatment (Table 3). However, there are long-term toxicities of
Fig 4. Effects of prednisolone on HIV disease progression: Primary Study Endpoint. Kaplan-Meyer estimate of progression to combined study
endpoint (onset of CDC stage-C-condition or drop of CD4 counts below 200) within the intent-to-treat (ITT) population (A) or the per protocol (PP) population
(B). C: Progression to AIDS-defining condition. All study participants who received HAART, but did not reach the study endpoint were censored for the KM
analysis.D-F andG-I: Post-hoc analyses for female study participants (D-F) and for male study participants (H-I) for progression to combined endpoint within
the ITT population (D, G), progression to combined endpoint within the PP population (E, H), and progression to AIDS-defining condition (F, I). A-I: P values
were calculated by log-rank (Mantel-Cox) analysis.
doi:10.1371/journal.pone.0146678.g004
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prednisolone that were not evaluated during this study, such as osteoporosis. An interesting
observation is the significant reduction of malaria cases in prednisolone-treated study partici-
pants compared with placebo-treated study participants (33 cases versus 59 cases, p = 0.0083,
Table 3), which merits further investigation in future trials. As we did not systematically screen
for malaria infections in this trial, this observation might as well be an effect of prednisolone-
mediated masking of malaria-triggered fever resulting in an underreporting of malaria cases in
the prednisolone arm. Also the condition “pain” was reported less frequently under predniso-
lone treatment than under placebo treatment (60 versus 88 cases, p = 0.0237, Table 3). We
observed more skin disorders such as rash or tinea under prednisolone treatment (79 versus 56
cases, p = 0.0540, Table 3). The body–mass-index (BMI) increased in both study arms during
the 2-year study time by about 1.5 BMI units and no differences between study participants
receiving prednisolone or placebo were observed (data not shown). We also measured glucose
levels in urine and no changes over time were observed in either treatment group (data not
shown).
Discussion
The primary endpoint of the study did not reveal any differences in disease progression
towards onset of AIDS (defined as a drop of CD4 counts below 200 cells/ml or the onset of a
clinical AIDS-defining condition). However, prednisolone decreased immune activation and
increased CD4 counts. Prednisolone treatment also caused an increase in HIV viral load. A per
protocol analysis stratifying for sex (post-hoc) showed a significant attenuation of disease pro-
gression in female study participants treated with prednisolone compared to placebo.
The study has potential limitations. First, the primary endpoint of the study, “progression to
AIDS”, contains both a laboratory surrogate marker (CD4 counts), as well as a purely clinical
endpoint (onset of an AIDS-defining condition). The majority of study participants who pro-
gressed to this combined endpoint met the CD4 criterion (15 versus 17 for prednisolone and
placebo, respectively), whereas only a much smaller fraction of study participants reached the
clinical endpoint “onset of AIDS-defining condition” (4 versus 11), and differences in this
purely clinical endpoint did not quite reach statistical significance (p = 0.0575). Since we can-
not exclude that prednisolone-mediated changes in CD4 counts could also be related to a dif-
ferent distribution of cells—instead of an increase in total numbers—the answer to the
question whether prednisolone treatment in HIV infection indeed improved health must be
given with caution. We suggest, however, that the observation of a long-lasting increase in CD4
counts over the entire two-year treatment period argues against a mere redistribution effect
and in favor of a true increase in CD4 numbers.
Second, the study has a two-year drop-out rate of about 24%, which is substantially higher
than the primary endpoint event rate of about 14% and therefore may compromise the
Kaplan-Meier-analysis. This drop-out rate (which is equivalent to an annual 12% loss-to fol-
low-up) is comparable to the loss-to-follow-up rates reported in many other clinical trials on
HIV drug adherence in Sub-Saharan Africa [29]. As the drop-out rate in the prednisolone arm
was similar to the drop-out rate in the placebo arm (22.09% versus 25.15%, respectively) we
suggest that there is reason to assume that the dropout rate may not have had a big distorting
effect on the results of the trial and we found no evidence that the drop-outs were related to
HIV infection.
Fig 5. Disease progression in male and female study participants. Kaplan-Meyer estimate of progression to combined study endpoint (onset of CDC
stage-C-condition or drop of CD4 counts below 200) within the intent-to-treat (ITT) population of study participants treated with placebo (A) or prednisolone
(B) stratified by sex. P values were calculated by log-rank (Mantel-Cox) analysis.
doi:10.1371/journal.pone.0146678.g005
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Fig 6. Progression to HAART as treated. Kaplan-Meyer estimate of progression to HAART as treated within the intent-to-treat (ITT) population (A) or the
per protocol (PP) population (B). Separate analyses for female study participants (B, E) and for male study participants (C, F) for progression to HART as
treated. P values were calculated by log-rank (Mantel-Cox) analysis.
doi:10.1371/journal.pone.0146678.g006
Fig 7. Study participants at risk.Number of study participants at risk within the intent-to-treat (ITT) population (A) or the per protocol (PP) population (B).
Separate analyses for female study participants (C, D) and for male study participants (E, F).
doi:10.1371/journal.pone.0146678.g007
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Third, stratification according to sex was a post-hoc analysis, and only in this post-hoc anal-
ysis we observed a statistically significant benefit for prednisolone in attenuation of disease pro-
gression in female study participants. By definition randomization is lost in post-hoc analyses
and the data must thus be considered with caution. Differences in outcome between male and
female study participants could be attributed to sex-specific differences in the immune system
as well as to different pharmacokinetics and pharmacodynamics of prednisolone in females
and males. Sex-specific differences in the immune responses have been known for decades and
have also been observed in HIV infection (reviewed in [28]), and one of these differences were
also directly observable in the baseline characteristics of this study, showing a higher CD4/CD8
ratio in females, in accordance to what has been reported by other groups [26]. In particular,
HIV-associated immune activation was found to be higher in females than in men [30], indi-
cating that immune intervention therapies might also have different results in females and
Fig 8. Effects of prednisolone on CD4 counts and CD4/CD8 ratio. A: Mean CD4 ± S.D. P-values were determined by 2way ANOVA.B: Mean CD4
changes ± S.D. relative to baseline and linear regression of the data. 2-year gains/losses were calculated from slope of linear regression. C: Mean ± S.D.
CD4/CD8-ratio and linear regression. B, C: P values on the right indicate non-zero hypotheses for the slope. P-value on the left for difference between the
two data sets was calculated by 2way ANOVA.D-F andG-I: Post-hoc analyses for female study participants (D-F) and for male study participants (H-I) for
absolute CD4 counts (D, G), CD4 relative CD4 changes (E, H), and CD4/CD8 ratio (F, I).
doi:10.1371/journal.pone.0146678.g008
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males. Pharmacokinetic reasons may also account for the observed differences. A study on
prednisolone pharmacokinetics in relation to sex and race found a higher AUC in females ver-
sus males, as well as both a higher clearance and a higher volume of distribution in males ver-
sus females [31]. These differences may explain why the fix, relatively low dose of 5 mg
prednisolone given in the study might have shown less activity in males. Moreover, when
adjusted to bodyweight, females received a 9% higher dose of prednisolone, which may also
have contributed to the observed differences between females and males.
Fig 9. Effects of prednisolone on immune activation and HIV viral load. A, E, I: Concentration of sCD14 was determined by ELISA from n = 134
(placebo) and n = 136 (prednisolone) available plasma samples collected at baseline, 3, 6 and 12 months. A: all sexes, E: females (nPlac = 106, nPred = 110),
I: males (nPlac = 28, nPred = 26). B, F, J: Concentration of sUPAR was determined by ELISA from n = 122 (placebo) and n = 124 (prednisolone) available
plasma samples collected at baseline, 3, 6 and 12 months. B: all sexes, F: females (nPlac = 95, nPred = 102), J: males (nPlac = 27, nPred = 22). A, B, E, F, I, J:
Data as means ± S.D. P-values were determined by 2-way ANOVA (difference between the two treatments over the whole time period) or by Wilcoxon
matched-pairs signed test (changes between Baseline and month 12). C, G, K: CD38/HLA-DR expression was determined by flow cytometry from n = 22
(placebo) and n = 30 (prednisolone) available frozen PBMC samples collected at baseline and 12 months. C: all sexes, G: females (nPlac = 19, nPred = 27), K:
males (nPlac = 3, nPred = 3). P-values were determined byWilcoxon matched-pairs signed test (changes between Baseline and month 12).D, H, L:HIV viral
load was determined from n = 86 (placebo) and n = 80 (prednisolone) available plasma pairs at baseline and month 12. D: all sexes, H: females (nPlac = 70,
nPred = 66), L: males (nPlac = 16, nPred = 14). P-values were determined byWilcoxon matched-pairs signed test (changes between Baseline and month 12)
and by Mann-Whitney test (comparison of month 12 placebo versus month 12 prednisolone).
doi:10.1371/journal.pone.0146678.g009
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Fourth, the data on immune activation and HIV viral load derive only from some time
points of the study and only from a limited number of samples, either due to limitations in
funding and/or lack of availability of samples. For example, HIV viral load data was deter-
mined from all study participants from whom we had both baseline and month 12 plasma sam-
ples available, corresponding to a total of 166 study participants (51% of the study population).
This selection has the bias of excluding, a priori, all study participants from this analysis who
either fulfilled the study before month 12 or who were lost to follow-up before month 12
(which combined account for about 25% of the study population). Changes in HIV viral load
detected in the month 12-samples compared to baseline may therefore not necessarily repre-
sent viral load changes in the rest of the study population.
Table 3. Adverse Events.
Adverse event (AE) Prednisolone Placebo P Value§
cases events cases events cases Events§§
general Any adverse event 144 669 143 711 1.0000 n.d.
Any serious AE 15 16 14 15 1.0000 n.d.
Any grade 3/4 AE 8 9 8 10 1.0000 n.d.
grade 3 event 7 8 8 9 1.0000 n.d.
grade 4 event 1 1 1 1 1.0000 n.d.
infections Herpes 15 16 12 14 0.6884 0.8546
Malaria 30 33 41 59 0.1794 0.0083*
Pneumonia 26 28 19 22 0.3354 0.4767
Respiratory tract 75 122 68 113 0.5031 0.5904
Tonsillitis 6 8 15 16 0.0689 0.1518
Tuberculosis 3 3 3 3 1.0000 0.6829
Urinary tract 24 30 24 28 1.0000 0.8948
Candidiasis 22 32 28 38 0.4424 0.5465
gastrointestinal symptoms Abdominal pain 33 38 31 41 0.8892 0.8202
Diarrhoe 24 32 34 41 0.1922 0.3446
Epigastric pain 8 12 12 13 0.4896 1.0000
Nausea 10 12 8 8 0.8092 0.5012
Peptic ulcer 2 3 6 6 0.2830 0.5045
Vomiting 4 4 3 3 1.0000 1.0000
cancers Kaposi sarcoma 0 0 1 1 1.0000 1.0000
common side effects of prednisolone Hyperglycemia 1 1 1 1 1.0000 0.4794
Fluid retention 0 0 1 1 1.0000 0.9855
Skin disorders 50 79 39 56 0.2137 0.0540
Hypertension 0 0 0 0 n.a. n.a.
Pain 37 60 58 88 0.0146* 0.0237*
others Fever 45 54 47 65 0.9021 0.3519
Neurol. disorders 5 5 5 5 1.0000 0.7515
Other# 71 99 63 88 0.4308 0.2479
#: conjunctivitis, otitis media, prolonged menstruation, dental pain, ﬂu-like symptoms, worm infections, dental pain, dizziness, numbness etc.
§) P from Χ2 calculation
§§) the maximum number of reported events per condition is 1956 (163 study participants x 12 visits). This number was used as the basis for the Χ2
calculation for number of events.
*) statistically signiﬁcant with p < 0.05.
doi:10.1371/journal.pone.0146678.t003
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The mechanism of the observed increase in HIV viral load is unclear. HIV viral load is influ-
enced by a variety of parameters and some of them have opposite effects on HIV replication,
including CD4 T cell activation (which is a prerequisite for productive infection and which
prednisolone would probably counteract) and CTL activity (which plays a major role in immu-
nological control of HIV replication, which is potentially inhibited by prednisolone treatment).
Low-dose prednisolone as investigated in this study has obviously shifted this balance towards
enhanced virus replication. Several previous clinical trials have studied the effects of higher-
dose corticosteroids on HIV infection and HIV infection: In a prospective, uncontrolled clini-
cal trial, Andrieu et al. found an increase in CD4 counts by 119 cells/μl within one year in anti-
retroviral-untreated HIV infection. Prednisolone was given at 0.3–0.5 mg/kg body weight
(about 4–6 times higher than in our study) and no changes in HIV viral load were detected [22,
23]. Elliott et al. studied the effects of prednisolone on HIV-associated pleural tuberculosis in
197 antiretroviral-untreated study participants in a double-blind, randomized placebo-con-
trolled clinical trial. Prednisolone was given at a dosage of 50 mg per day (which is ten times
higher than in our study) for two weeks and then tapered down to 15 mg in the following 6
weeks before it was stopped. No changes in HIV viral load or CD4 counts have been detected
[32]. Wallis et al. studied the effects of prednisone on antiretroviral-treated HIV infection in a
randomized, placebo-controlled trial including 24 subjects. Prednisone or placebo was given at
a dose of 40 mg per day (8 times higher than in our study) for 8 weeks, followed by a 4-week
period of 20 mg per day. The authors observed an increase in CD4 counts (> 40%, p = 0.08)
and no changes in (mostly antiretroviral-suppressed) HIV viral load. Two individuals treated
with prednisone were found to have asymptomatic osteonecrosis of the hip [33].
Although the CD4-increasing effects of prednisolone in our study were significant, the CD4
gains are low compared to what is achievable with antiretroviral therapy, even in resource-lim-
ited settings [34]. Moreover, HIV viral load has approximately tripled in prednisolone-treated
study participants and the study failed to show a clinical benefit for the patients in its primary
endpoint. And finally, not all potential toxicities of long-term treatment with low-dose prednis-
olone, including osteoporosis, have been analyzed in this trial. The here-presented data there-
fore does not justify prednisolone therapy in HIV infection as an alternative to HAART, given
both the greater efficacy of HAART, its well-known long-term safety, and its beneficial effects
in reducing the risk of HIV transmission [35, 36]. In line with this, the results of this study
should not be misinterpreted to diminish our efforts to provide HAART worldwide for
everyone.
Chronic immune activation has long been suspected to be a factor in HIV disease progres-
sion [2, 3, 5–8, 10, 12, 27, 37, 38]. Although there is an excellent correlation between immune
activation and HIV disease progression, there is no direct and definitive proof yet that inhibi-
tion of immune activation indeed improves health. The here-presented clinical-endpoint
study, in which we investigated the effects of an intervention that directly targets immune acti-
vation in HIV infection, provides first data to answer the question of whether a therapeutic
decrease of HIV immune activation translates into clinical benefit and may be informative for
future clinical trails aiming to develop immune modulatory therapies to be combined with clas-
sical HAART.
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